Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

New Molecules in Age Related Macular Degeneration

Yaş Tip Yaşa Bağlı Makula Dejenerasyonunda Yeni Moleküller

Pages
53–62
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article aims to update the information through these studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age-related macular degeneration (AMD), especially in the wet AMD group, has become the leading cause of visual impairment with increased life expectancy.
📊
Key Findings & Data:Following the Argon Laser Pho- tocoagulation, which is a historical event, Photodynamic Thera- py aims to protect and reduce vision loss, however with the help of anti-VEGF agents it is possible for the fi rst time to increase visual acuity.
💡
Conclusion & Impact:This article aims to update the information through these studies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age-related macular degeneration (AMD), especially in the wet AMD group, has become the leading cause of visual impairment with increased life expectancy. Following the Argon Laser Pho- tocoagulation, which is a historical event, Photodynamic Thera- py aims to protect and reduce vision loss, however with the help of anti-VEGF agents it is possible for the fi rst time to increase visual acuity. After the development of limited eff ective anti-VEGF agents in the enhancement of visual acuity, other molecules that are eff ec- tive in the pathophysiological mechanisms of the disease and new treatment protocols are intensively studied. This article aims to update the information through these studies.

Özet

Yaşa Bağlı Makula Dejeneresansı özellikle de Yaş tip grubundaki olgular, artan yaşam ömrü ile beraber en önemli görme kaybı nedeni haline gelmiştir. Tarihsel önemi olan Argon Laser Fotoko- agülasyonu takiben Fotodinamik Tedavi ile görme kaybının azal- tılması, görmenin korunması amaçlanmasına rağmen, anti-VE- GF ajanlar ile ilk kez görme artışı sağlanabilmiştir. Görme artışını sağlamada sınırlı etkin anti-VEGF ajanların ge- liştirilmesinden sonra, hastalığın fizyopatolojik mekanizmala- rında etkili diğer moleküller ve yeni tedavi protokolleri yoğun olarak çalışılmaktadır. Bu makale ile bu çalışmalar üzerinden bilgi güncellemesi amaçlanmaktadır.

🔖

Cite This Article

ÜNAL, M. (2017). New Molecules in Age Related Macular Degeneration. Retina-Vitreus, Cilt: 26 - Sayı: 0, 53–62. https://ajindex.com/articles/304920

References (9)

  1. Martina Santarelli, Laura Diplotti, Francesco Samassa, Daniele Veritti, et al. Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opin, Pharmacother (2015) 16(12) Peter K, Kaiser, MD Emerging Therapies for Neovascular Age-Related Macular Degeneration Ophthalmology Volume 120, Number 5, Supplement, May 2013
  2. Michael John Tolentino, Abrahan Dennrick, Elizabeth John & Michael Steven Tolentino Drugs in Phase II clinical trials fort he treatment of age-related macular degeneration Expert Opin, Investing Drugs (2015) 24(2) Paula E, Pecen and Peter K. Kaiser Current phase 1/2 research for neovascular age-related macular degeneration Ophthalmo- logy Volume 26, Number 3, May 2015
  3. Makota Ishilkawa, Daisuke Jin, Yu Sawada, Sanae Abe and Ta- keshi Yoshitomi Future therapies of wet age-related macular degeneration Journal of Ophthalmology. Volume 2015 Adiel G Smith & Peter K Kaiser Emerging treatments for wet age-related macular degeneration Expert Opin, Emerging Drugs (2014) 19(1) Victor M. Villegas, Luis A. Aranguren, Jaclyn L.Kıvach, Stephen G. Schwartz and Harry W.Flynn Jr. Current advances in the tre- atment of neovascular age-related macular degeneration Expert Opinion on Drug Delivery 2016
  4. Martin DF. Maguire MG, Comparison of age-related Macular Degeeneration Treatments Trials (CATT) Research Group, et al. Ranibizumab and bevacizumab for treatment of age-rela- ted macular degenaration2 year results. Ophthalmology 2012; 119(7):1388-1398
  5. Honda M, Asai T, Oku N, et al. Liposomes and nanotechnology in drug development: focus on ocular targets. Int J Nanomedicine. 2013;8:495-503
  6. Farjo Km, Ma JX. The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenesis Res. 2010;2:21 Kompella UB, Amrite AC, Pacha Ravil R, et al. Nanomedicines for the back of the eye drug delivery, gene delivery and ima- ging. Prog Retin Eye Res. 2013;36:172-198
  7. Shelke Nb, Kadam R, Tyagi P, et al. Intravitreal poly (L-lactide) microparticles sustain retinal and choroidal delivery of TG 0054 a hydrophilic drug intended for neovascular diseases. Drug Deliv Trans Res. 2011;1:76-90
  8. Kang Derwent JJ, Mieler WF. Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye. Trans Am Ophthalmol Soc. 2008;106:206-213
  9. Wang CH, Hwang YS, Chiang PR, et al. Extended release of be- vacizumab by thermosensitive biodegradable and biocompatible hydrogel, Biomacromolecules 2012;13:40-48 Kaiser PK Anti-VEGF therapy